Contrast-enhancedspectralmammography(CESM)isanoveltechniqueusedfor detection of tumour vascularity by imaging the moment in which contrast, delivered to the lesion by blood vessels, leaks out of them, and flows out through lymphaticvessels. Inourstudy,weincluded174womenforwhomspectralmammographywasper-formedfordiagnosticpurposes.TherelationshipbetweenenhancementinCESM and blood vessel density (BVD), lymphatic vessel density (LVD) or the percentageoffieldswithatleastonelymphaticvessel(distributionofpodoplanin-positive vessels-DPV)andotherrelatedparameterswasassessedin55cases.BVD,LVD andDPVwereassessedimmunohistochemically,applyingpodoplaninandCD31/ CD34asmarkersoflymphaticandbloodvessels,respectively. Thesensitivity(indetectionofmalignantlesions)ofCESMwas100%,whileits specificity-39%.WefoundasignificantpositivecorrelationbetweentheintensityofenhancementinCESMandBVD(p=0.007,r=0.357)andanegative correlationbetweentheintensityofenhancementinCESMandDPV(p=0.003, r=-0.390).LesionswiththehighestenhancementinCESMshowedahighnumberofbloodvesselsandalownumberoflymphatics. Conclusions:1)CESMisamethodcharacterizedbyhighsensitivityandacceptable specificity;2)thecorrelationbetweenCESMresultsandblood/lymphaticvesseldensityconfirmsitsutilityindetectionoftissueangiogenesisand/orlymphangiogenesis.
Introduction
Angiogenesis,whichisacommonfeatureofinvasivecarcinomas,isaprocessofnewbloodvesselformation [1, 2] .Prognosticsignificanceofbloodvessel density(BVD)inbreastcancerwasreportedbysome authors [1, 3, 4, 5] ,andquestionedbyothers [6, 7] . Notonlythenumberofbloodvesselsbutalsotheir permeabilityisdifferentinmalignanciesascompared to normal tissues [8, 9, 10, 11] . Contrary to blood vessels,notallcarcinomaselicitformationofanew lymphatic drainage system [1] . Nevertheless, a relationshipbetweenthenumberoflymphaticvessels andpatientsurvivalratehasbeenreportedbysome researchers [3, 4, 6, 12, 13, 14, 15] .
Utilizingtheknowledgeabouttumourangio-and lymphangiogenesis,thefollowingmethodshavebeen recently developed for in vivo vascularity imaging: ultrasound(US)performedaftercontrastadministration, breast magnetic resonance imaging (MRI) and contrast-enhanced spectral mammography (CESM). Contrast-enhancedUSwasfirstusedinbreastimaging toincreasethediagnosticaccuracyofcolourorpower Doppler imaging [16, 17, 18, 19] . This was mainly due to improved visualization of the intratumoural vasculararchitectureaftercontrastagentadministration. Different time intensity curves were found for malignant and benign breast masses [20] . Further study revealed that breast mass contrast-enhanced ultrasonography findings correlated with histological features [21] .Despitegoodresultsofthestudiespresented above, the cost of contrast agent used in US examinationwastoohigh;therefore,theapplicationof thismethodinbreastcancerdiagnosticsislimited.The lastoftheabove-mentionedmethodsisMRI.Although breastMRIisthoughttobethemostsensitiveimaging technique for breast cancer detection and assessment oftheextentofthedisease,itisoftennotavailableto womenbecauseoffinancialreasons,mainlythelackof insurancecoverage.Moreover,thequalityofbreastMRI candiffersignificantlyacrosspractices [22, 23, 24, 25] .
Contrast-enhanced spectral mammography is a novel technique accepted by the Food and Drug Administration(FDA)forclinicaluseintheU.S.in 2011andintensivelydevelopedinthelastfewyears. Themainapplianceofthismethodistheassessment of tumour neoangiogenesis by administration of a chelated iodine-based X-ray contrast agent. Contrast-enhanced spectral mammography can be performed by using a current digital mammography systemwithsomespecificsoftwareandhardwareadaptationsforimageacquisitionandprocessing.Contrast-enhancedspectralmammographyisofinterest inthenon-screeningsettingandhasthepotentialto increasecancerdetectionrateandtoimprovecancer staging,particularlytheassessmentoftheextentof disease. Contrast-enhanced spectral mammography is usedfordetectionoftumourvascularitybyimaging themomentinwhichcontrast,deliveredtothelesion by blood vessels, leaks out of them, and flows out throughlymphaticvessels.Therefore,hypothetically, thenumberofbloodvesselsandlymphaticvesselsin thelesion,assessedintissuesections,shouldcorrelate withtheresultsofCESM.Thispromptedustostudy therelationshipbetweenenhancementinCESMand bloodvesseldensity(BVD)orlymphaticvesseldensity(LVD).Inordertogainabetterinsightintothe problem,weanalysedvessels(bloodandlymphatic) without a visible lumen, with a lumen, and all of them, separately. Additionally, in the case of lymphaticvessels,wedeterminedthepercentageoffields withatleastonelymphaticvessel.
Material and methods

Patients
Between2011and2013,174women(meanage 55.7±0.8[SE])withglandularbreastanatomyreported in the previous mammography examination orwithalesionrequiringfurtherdiagnosticsunderwentspectralmammographyfordiagnosticpurposes. In this group 191 contrast-enhancing foci (suspectedlesions)werefound.Histologicalexamination of lesions enhancing in CESM was performed after core biopsy or vacuum-assisted core biopsy guided byultrasonographyormammography.Thisverification confirmed the presence of 191 lesions. In 157 patientstherewasasinglelesion,whilein17women there were 2 lesions. There were 95 invasive carcinomas,19in situcarcinomasand77benignlesions (details are presented in Table I ). Additionally, as a control, we included 11 sections of normal breast tissue from Madden's modified mastectomy specimens,fromquadrantsofbreastinwhichcancertissue wasabsent. Thisstudywasperformedincompliancewiththe Declaration of Helsinki and it received the approvaloftheEthicalCommitteeattheRegionalMedical ChamberinKrakow.
Methodology
Contrast-enhanced spectral mammography
All CESM examinations were performed with a digital mammography device developed by GE Healthcare(SenoBright)allowingdual-energyCESM acquisitions.Beforeexposurepatientsweregivenan intravenousinjectionofnon-ioniccontrastagent(Ultravist370,1.5ml/kgofbodyweight),usingapowerinjector(Covidien,OptistarEliteInjector)atarate of3ml/swithaboluschaserofsaline.Twominutes and4minutes(forMLOandCC,respectively)after theinitiationofcontrastagentadministration,apair of exposures (low-and high-energy) in each view (MLOandCC)wasperformedautomatically.Proper imageprocessingallowedforcombinationoflow-energyandhigh-energyimagestogeneratesubtracted images with contrast agent uptake information in eachview.
All images were evaluated by one radiologist, blindtopatients'history.Thefollowingdatawererecordedforeachtumour:presenceorabsenceofcon- 
Immunohistochemistry
Immunohistochemistry was performed in 55 lesions (12 benign lesions: 4 regressive changes, 5 fibroadenomas, 1 hamartoma, 2 usual ductal hyperplasia; 6 in situ carcinomas; 37 invasive carcinomas: 34ductalcarcinomas,1lobularcarcinoma,1invasive papillary carcinoma, 1 Paget disease of the nipple), on formalin-fixed, paraffin-embedded tissue sections (4µmthick),whichweremountedonSuperFrostslides (Menzel-Gläser,Braunschweig,Germany),dewaxedin xyleneandrehydratedthroughaseriesofalcohols.AntigenretrievalwasperformedwithTargetRetrievalSolution(TRS,pH=6.1,96°Cfor50min,AgilentTechnologies Dako Denmark A/S, Glostrup, Denmark); quenching the activity of endogenous peroxidases was performed with 0.3% H 2 O 2 in 100% methanol (30minincubation),whileblockingofunspecificantibodybindingwasperformedwithUltraVisionProtein Block(5min,ThermoScientific,Fremont,USA).We usedanti-podoplaninantibody(cloneD2-40,dilution1 :100;CellMarque,Rocklin,California,USA)forvisualizationoflymphaticvessels,anti-CD34antibody(clone QBEnd10,dilution1:50;AgilentTechnologiesDako DenmarkA/S,Glostrup,Denmark)andanti-CD31an-tibody(clone1A10,dilution1:50,Leica-Biosystems, BuffaloGrove,USA)forvisualizationofbloodvessels. BrightVision (30 min, room temperature; Immunologic, Duiven, Netherlands) was used to visualize the presence of vessels. In the double-staining procedure VIP(violetcolour)wasusedasaperoxidasesubstrate (Vector Laboratories, Burnligame, USA) for visualization of CD34 ( Fig. 1A, B ; arrow) or CD31 (Fig. 1C , E,G;arrow),whileDAB(browncolour)wasusedfor podoplanin (Fig.1A, C,E,G;arrowhead).Eventually, slideswerecounterstainedwithMayer'shematoxylin.
Evaluation of immunohistochemistry
Distribution of podoplanin-positive vessels (DPV) was assessed in the whole examined specimen (over 4microscopicfieldswererequiredforitsassessment). Ineachfield(10×objective)theabsenceorpresenceof lymphatics(withlumen,withoutlumenorwithemboli)wasrecorded.Basedontheaforementionedassessment,eachfieldwasclassifiedaspositive(withatleast one podoplanin-positive vessel) or negative (without lymphatics).Eventually,thepercentageoffieldswith atleastonelymphaticvesselwascalculated(DPV).
Additionally, we assessed (in more than 4 microscopic fields) the density of CD34-positive or CD31-positive blood vessels and podoplanin-positivelymphaticvessels(CD34BVDorCD31BVDand LVD, respectively). Blood vessel density and LVD were expressed as mean number of vessels (blood and lymphatic, respectively) per microscopic field (10×objectivemagnification,area0.848mm The analysis was performed with digital image analysisusingaCX41microscope,SC30cameraand Cell D software (Olympus Europa GmbH, Hamburg,Germany).Vesselsweremarkedmanuallyand thencountedautomatically.AllevaluationsweredeterminedwithouttheknowledgeofCESMresults.
Becauseinsomenon-invasivelesionsandnormal breast tissue CD34 immunopositivity of myofibroblasts (surrounding normal ducts, lobules, and intraductal carcinomas) hindered calculation of BVD (Fig. 1D, star) , we decided to apply CD31 instead. Therefore, we compared BVDsmall, BVDlumen andBVD,obtainedusingCD31andCD34,totest whetherthesemarkerscanbeusedinterchangeably. Forthispurpose,serialsectionsfrom6malignantle-sionswerestainedwith:(1)CD31(VIP)/podoplanin (DAB) (Fig. 1C , E, G) and (2) CD34 (VIP)/podoplanin(DAB) (Fig.1D,F,H) .Thenweselectedmicroscopicfieldswiththesamefragmentoftissuefrom CD31-and CD34-stained slides. Next, four paired fields(oneforCD31,theotherforCD34)foreachof sixtumoursweretaken(insum24fieldsforCD31 andforCD34).Finally,weassessedBVDsmall,BVDlumenandBVDbothforCD31andforCD34:CD31BVDsmall, CD34BVDsmall, CD31BVDlumen, CD34BVDlumen,CD31BVDandCD34BVD.
Statistical analysis
The STATISTICA v. 10 software (StatSoft, Inc. Tulsa, OK, USA) was used for all calculations. The p value < 0.05 was considered significant. Differencesbetweengroupswereestimatedusingone-way analysis of variance (ANOVA) or Kruskal-Wallis ANOVA. After one-way analysis of variance posthocTukey'sHSDtestwasperformed.TheWilcoxon signed-ranktest(apaireddifferencetest)wasusedto comparetwomatchedsamplesandtoassesswhether their population mean ranks differ (repeated measurements using different antibodies). The Pearson correlationcoefficientwasusedtotestforacorrelation between two continuous variables. Spearman's rank correlation coefficient was applied to measure statistical dependence between two variables. Pear- 
Results
Expression of podoplanin, CD34 and CD31
Podoplanin expression was found in endothelial cellsoflymphaticvessels (Fig.1A,C-H;arrowhead) , cancer-associatedstromalfibroblasts( Fig.1G-H ;asterisk represents weak staining), myoepithelial cells surroundingducts,lobulesorin situcarcinomas (Fig.  1C,D;blackarrowhead) . CD34expressionwasfoundinendothelialcellsof bloodvessels (Fig.1A,arrow; 1Barrowandarrow-head)andmyofibroblastssurroundingducts,lobules or in situ carcinomas (Fig. 1D, asterisk) . Because CD34-positive myofibroblasts (observed in benign lesions)hinderedobtainingreliableresultsforBVD, insomecasesweapplieddoublestainingwithCD31 (violetcolour)andpodoplanin(browncolour).
CD31 was present in endothelial cells of blood vessels (Fig. 1C , E, G; arrow) and absent in myofibroblastssurroundingducts,lobulesorin situcarcinomas (Fig.1C)thatwereimmunopositiveforCD34  (Fig. 1D, asterisk) . Additionally, CD31 expression was found in leukocytes infiltrating tumour stroma ( Fig.1G;blackarrowhead) .
Blood and lymphatic vessel density in normal breast tissue, benign lesions, in situ carcinomas and invasive carcinomas
Some invasive carcinomas (18/37 cases, 48.6%) presentednolymphaticsintheintratumouralorperipheralarea (Fig.1B) Invasive carcinomas presented lower values of LVDsmallandDPVthanotherlesiontypes( Fig.2A) , whilenormalbreasttissuepresentedhighervaluesof LVDlumen and LVD than all other lesions (invasive andin situcarcinomasandbenignlesions) (Fig.2C,E) . Invasiveandin situcarcinomas,ascomparedtobenign lesionsandnormalbreasttissue,werecharacterizedby significantlyhigherBVDsmallandBVD (Fig.2B,F) .
WefoundanegativecorrelationbetweenBVDs In the group of invasive carcinomas BVD was not correlatedwithLVD(p>0.05forstudiedparameters).
Comparison of blood vessel density assessed based on CD31 and CD34 immunopositivity in endothelial cells
In all analysed cases CD31 immunopositivity of endothelium (Fig.1C,E,G) wasweakerthanCD34 immunopositivity (Fig. 1D, F, H) . Nevertheless, no difference was found between: (1) CD34BVDsmall (50.5 ±13.2; mean ± SD), and CD31BVDsmall (51.4 ±12.5) (p = 0.683); (2) CD34BVDlumen (7.6 ±7.6) and CD31BVDlumen (7.9 ±3.5) (p=0.683)aswellas(3)CD34BVD(68.1±10.5) andCD31BVD(69.3±11.7)(p=0.683).ThisconvincedusthatwecanuseCD31incaseswheremyo-fibroblastCD34immunopositivityhinderedobtain-ingreliableresultsofBVD( Fig.1D;asterisk) .
Contrast enhancement in contrast-enhanced spectral mammography and histological parameters
ThesensitivityofCESMwas100%:allcarcinomas (invasive or in situ) (114 cases) presented enhancement (weak, medium or strong) in CESM. On the otherhand,specificityofCESMwas39.0%:noenhancementinCESMwasobserved in30/77 benign lesions (Table II) In the group of invasive carcinomas, there was a significant positive correlation between enhancementinCESMand:pT,pN(p=0.003,r=0.314; p=0.002,r=0.333,respectively;Spearmancorrelationcoefficient).Moreover,wefoundasignificant positivecorrelationbetweenlesionsizeinCESMand bothpTandpN(p=0.001,r=0.362;p=0.001, r=0.340).
Patients with benign lesions were significantly younger (53.3 ±9.9: mean age ± SD) than these within situ(56.5±9.3)orinvasivecarcinomas(57.5 ±11.3)(p=0.021fromKruskal-Wallistest).
Correlations between contrast enhancement in contrast-enhanced spectral mammography and parameters related to blood and lymphatic vessel density
WithSpearman'srankcorrelation,wefoundasignificantpositivecorrelationbetweentheintensityof (Fig. 3C , E, G) in cases with strong enhancementinCESM,ascomparedtothosewithno enhancementinCESM.
There was a statistically significant relationship betweenenhancementinCESMandpresenceorabsenceoflymphaticvessels(p=0.047).Inalllesions (5cases,100%)withnoenhancementinCESM,lymphaticvesselswerepresent.However,in50%(13/26 cases)oflesionswithstrongenhancementinCESM nolymphaticswerefound.Inlesionswithweakand medium enhancement in CESM there were 71.4% (5/7 cases) and 76.5% (13/17 cases) of cases with lymphaticvessels,respectively.
Benignlesionswithfalse-positiveresultsinCESM (thepresenceofenhancementinCESM,n=5)had ahighernumberofbloodvessels(BVD)andalower numberoflymphaticvessels(DPV)ascomparedto benignlesionswithtrue-negativeresults(lackofenhancementinCESM,n=7 
Discussion
Tothebestofourknowledge,forthefirsttimewe foundthatthestrongestenhancementinCESMcharacterizeslesionswithahighnumberofbloodvessels andalownumberoflymphatics(ortheirpoordistribution: DPV). This result confirms that the CESM technique detects and/or measures angio-/lymphangiogenesisofthelesion,afterintravenousinjectionof anon-ioniccontrastagent(Ultravist370)andduring apairofbreastexposures(low-andhigh-energy)in eachview [26, 27] .Assuggestedbyourresults,the enhancement in CESM is present when non-ionic contrastagentisprofuselydeliveredtobreasttissues throughadensenetworkofbloodvessels,leaksout fromthecapillariesand"getsstuck"inthetissuebecauseofthelownumberoflymphatics,hinderingits outflow. In contrast, in tissues with a high number oflymphaticvesselsandarelativelylownumberof blood vessels (benign lesions and normal breast tissue,asconfirmedbyourresults)theoutflowofcontrastisnotperturbed.Therefore,aswespeculate,no enhancementisobservedduringbreastexposure(no enhancement in CESM). The relationship between high number of blood vessels and intensity of enhancementinCESMmightbeadditionallyrelatedto lesserselectivityandhigherpermeabilityoftumour Table II vessels as compared to normal vessels (presumably duetolarge"gaps"betweenendothelialcellsanddiscontinuity of the vascular basement membrane) [8, 9, 10, 11] .
These speculations are clearly confirmed by an analysis performed by us, separately for benign lesionsandcarcinomas.Benignlesionswithfalse-positiveresults(presenceofenhancementinCESM),as compared to benign lesions with true-negative results(lackofenhancementinCESM),werecharacterizedbyahighernumberofbloodvessels(expressed asBVD)andalownumberoflymphaticvessels(expressedasDPV).Asimilartendencywasobservedin thegroupofinvasive/in situcarcinomas,inwhichthe strong enhancement in CESM (all carcinomas were true-positive)wasrelatedtoalowernumberoflymphaticsandahighnumberofbloodvessels.
The relationship between breast cancer vascularity and results of imaging techniques detecting tumour angiogenesis has also been studied by otherresearchers [26, 28, 29, 30] .FortheCESMtechnique,Dormainet al. [27] reportedastatisticallyinsignificanttrendtowardhigherintratumouralBVD in breast cancer patients with true-positive results ascomparedtofalse-negatives.Thisresultissimilar toours:fortrue-positivecancerpatients(wedidnot find false-negatives) we found significantly higher BVD in carcinomas with medium/strong enhancementinCESM.Thediscrepancybetweentheaforementionedresultsmightbetheeffectofthesmaller numberofcasesreportedbyDormainet al. [27] and a different method of BVD assessment. A significant positive correlation between BVD and lesion enhancementinmagneticresonancewasalsoreported [28, 29, 30] .However,nocorrelationwasfound betweenenhancementandLVD [28] .
In the present study, 51.4% of invasive carcinomas presented lymphatics in the intratumoural or peripheralarea.Thisiswithintherangeofourpreviousresultsinfemalebreastcancer(79.3% [31, 32] and male breast cancer (77% [33] ) and within the rangeofotherauthors'results(50% [5] ,85% [34] ). Moreover,invasivecarcinomaspresentedlowerLVD (LVDsmallandDPV)thanotherlesiontypes,while normalbreasttissuepresentedhighervaluesthanall otherlesions(benignlesions,in situ/invasivecarcinomas).OurresultsconfirmthestatementofVermeulen et al. [1] that not all carcinomas elicit formation of anewlymphaticdrainagesystemandsomeofthem usepre-existinglymphaticvesselsfromnormaltissue. Aninverserelationwasobservedforbloodvessels (whichwerepresentinallanalysedtissues):invasive andin situcarcinomas,ascomparedtobenignlesions andnormalbreasttissue,werecharacterizedbysignificantlyhigherBVD.Thisresultconfirmstheexistenceoftumourangiogenesis [1, 2] . ThenegativecorrelationbetweenBVDandLVD found by us, for all analysed tissues (except for invasive carcinomas), as well as previously described results, confirms that malignant breast lesions elicitangiogenesis [1, 2] ,butonlysomeofthemarein a position to activate lymphangiogenesis [1] . This featureoftissuescanbeexploitedbyimagingtechniques using contrast, which is delivered with efficiencyproportionaltoBVD,partiallyleaksoutfrom thecapillaries(withhigherintensityintumourvesselsbecauseoftheirpermeability)andisdrainedproportionally to LVD. In cases with an abnormal (as compared to normal tissue) proportion of both the above-mentionedvesseltypes,contrastaccumulation intissuemaytakeplace,which,ontheotherhand, mightbevisualizedduringexposure.
Interestingly, two parameters describing LVDdistribution of podoplanin-positive vessels (DPV) and number of lymphatics with a lumen (LVDlumen) -correlated the most significantly (with the lowest p-values) with histology and enhancement in CESM. This result suggests that normal breast tissue, benign lesions and carcinomas differ in the number of lymphatic vessels with a lumen and in distribution of all lymphatics. This, on the other hand,suggeststheneedforstudiesontheprognostic significanceofthetwoabove-mentionedparameters (DPVandLVDlumen).Inthecaseofbloodvessels, themostsignificantcorrelationwithhistologywas foundinthecaseofbloodvesselswithoutalumen (BVDsmall), suggesting intensive angiogenesis [1] in carcinomas as compared to benign lesions and normaltissue.
The utility of contrast-enhanced spectral mammographymightbeconfirmedbystrongcorrelation between the size of the lesion measured on CESM and: the size of the lesion measured on histological section (pT) (which was found by us and other researchers [27] andpNstatus(foundinourstudy).
In our study, the sensitivity of CESM was 100% and is comparable to the results of other researchers,whereitrangedfrom63.5to100% [35, 36, 37, 38] . Moreover, in the group of carcinomas (in situ and invasive)wefoundasignificantrelationshipbetweenthedegreeofenhancementinCESMandhistology (strong enhancement characterized invasive carcinomas).SpecificityofCESMreportedbyuswas relatively high (39%) and might suggest that some features of neoplastic angiogenesis might begin in selected benign lesions, before the development of malignantphenotype.
We plan to enlarge the group of cancer patients andstudytherelationshipbetweenhistologicalcharacteristics of tumours (other than lymphatic/blood vessel density) and their degree of enhancement in CESM as well as the prognostic significance of the aforementionedparameters.
Contrast-enhanced spectral mammography, similarly to other diagnostic methods, has the following limitations: (1) enhancement of benign lesions (it is worthmentioning,however,thatbenignlesionsmay enhancenotonlyinCESMbutalsoinMRI);(2)lack ofpossibilityofdrawinganenhancementcurve:the shape of the curve usually indicates the character of thelesion,whichinmanycasescanreducethenumberofunnecessarysurgicalprocedures;(3)20%high-erradiationdoseofCESMincomparisontoMG;(4) lackofunambiguousclassificationdescribingthetype andgradeofbreastlesionsinCESM:sofar,lesionassessmentinCESMhasbeensubjective,andotherimagingmethodshavetobeusedforverificationofthe lesion; (5) inability to perform biopsy under CESM guidance: lesion enhancement in CESM is transient and lesions not visible in other methods require exposing patients to another contrast administration and marker placement under CESM control; (6) Additionally to studying the correlation between tumour vascularity and enhancement in CESM, we compared the staining pattern of anti-CD34 and anti-CD31.TheimmunoreactivityofCD34-,podoplaninwasthesameasdescribedanddiscussedinour previous studies [31, 32, 33, 39] or as reported by otherauthors [41] .
InsomecaseswedecidedtoapplyCD31forcal-culation of BVD, because in some non-invasive lesionsandnormalbreasttissueCD34immunoposi-tivityofmyofibroblastshinderedcalculationofthis parameter. Therefore, we compared BVDsmall, BVDlumen and BVD, obtained using CD31 and CD34.Wefoundveryhighaccordancebetweenthe resultsinthecaseofalltypesofbloodvessels:with a lumen, without a lumen, and all of them. This finding confirmed previous reports suggesting the same staining pattern and intensity of CD31 and CD34staininginbloodvesselsoftheskin [41, 42] , bone marrow, kidney and lung [41] . In our study, occasional and irregular expression of CD31 and CD34 in lymphatic vessels [41, 42] did not influence assessment of BVD because of application of podoplaninasamarkeroflymphaticvessels,inthe double-stainingprocedure.
Conclusions
Contrast-enhancedspectralmammographymight be recommended as a method with high sensitivity forbreastcancerdiagnostics. Thecorrelationbetweenintensityofenhancement in CESM and blood/lymphatic vessel density confirms that CESM is the method of detection of tissue'sbloodandlymphaticvesseldensity.
Existence of a correlation between CESM results andlymphatic/bloodvesseldensity(whicharepotential prognostic factors) suggests that, in the future, CESMmightbringsomeprognosticinformationfor breastcancerpatients.
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